Leishmaniasis Supply Barriers in Africa - procurement perspective

Help us improve access to life-savings medicine for a neglected disease

This survey aims to explore barriers to effective supply of drugs to treat leishmaniasis, a killing disease. If you are doing procurement for countries in eastern Africa region, particularly in Ethiopia, Kenya, Somalia, South Sudan, Sudan and Uganda, then we'd like to hear from YOU!

PLEASE TAKE 5 MINUTES OF YOUR TIME TO ANSWER THIS SURVEY.

Thank you

Question Title

* 1. Which of the anti-leishmanial commodities below that you/your agency had/have been procuring? (Check all that apply)

Sodium stibogluconate

Paromomycin

Liposomal amphotericin B (AmBisome®)

Meglumine antimoniate (Glucantime®)

Pentostam®

Miltefosine

rK39 RDT Brand__________________

Other (please specify)

Question Title

* 2. How have you previously procured leishmaniasis medicines and diagnostics for countries in eastern Africa?

Open tender

Restricted tender

DIrect procurement from supplier

DIrect procurement from manufacturer

Using international procurement agents

Other (please specify)

Question Title

* 3. In your view, which of the issues below was the most important in procurement of leishmaniasis drugs and diagnostics?

Legal registration in country destination

Quality

The price

Punctual delivery

Accurate need calculation

Other (please specify)

Question Title

* 4. Have you experienced delay in the procurement of any of the anti leishmanial drug?

Yes

Don’t know

Question Title

* 5. What was the reason for the last procurement delay?

Not enough supplier/manufacturer

Regulatory requirement in country destination

Complex procedures in country destination (importation, custom..)

Inaccurate need estimation

Quality of the product

Price of the product

Other (please specify)

Question Title

* 6. On a scale from 1 (not at all important) to 5 (extremely important), please rate how each issue acts as supply barrier to leishmanial drugs and diagnostics, according to you. By importance, we mean how critical the issue is in access to anti-leishmanial commodities. The more you feel the issue is important.

	1-Not at all important	2	3	4	5-Extremely important	N/A
The product is not registered in the country	The product is not registered in the country 1-Not at all important	The product is not registered in the country 2	The product is not registered in the country 3	The product is not registered in the country 4	The product is not registered in the country 5-Extremely important	The product is not registered in the country N/A
Limited number of suppliers	Limited number of suppliers 1-Not at all important	Limited number of suppliers 2	Limited number of suppliers 3	Limited number of suppliers 4	Limited number of suppliers 5-Extremely important	Limited number of suppliers N/A
Procurement is not done through government	Procurement is not done through government 1-Not at all important	Procurement is not done through government 2	Procurement is not done through government 3	Procurement is not done through government 4	Procurement is not done through government 5-Extremely important	Procurement is not done through government N/A
The drug is not included in the national medicine list	The drug is not included in the national medicine list 1-Not at all important	The drug is not included in the national medicine list 2	The drug is not included in the national medicine list 3	The drug is not included in the national medicine list 4	The drug is not included in the national medicine list 5-Extremely important	The drug is not included in the national medicine list N/A
Quality of the product	Quality of the product 1-Not at all important	Quality of the product 2	Quality of the product 3	Quality of the product 4	Quality of the product 5-Extremely important	Quality of the product N/A
Lack of forecasting	Lack of forecasting 1-Not at all important	Lack of forecasting 2	Lack of forecasting 3	Lack of forecasting 4	Lack of forecasting 5-Extremely important	Lack of forecasting N/A
Transport difficulties/ delivery to health facility	Transport difficulties/ delivery to health facility 1-Not at all important	Transport difficulties/ delivery to health facility 2	Transport difficulties/ delivery to health facility 3	Transport difficulties/ delivery to health facility 4	Transport difficulties/ delivery to health facility 5-Extremely important	Transport difficulties/ delivery to health facility N/A
Importation issue	Importation issue 1-Not at all important	Importation issue 2	Importation issue 3	Importation issue 4	Importation issue 5-Extremely important	Importation issue N/A
No control programme taking responsibility	No control programme taking responsibility 1-Not at all important	No control programme taking responsibility 2	No control programme taking responsibility 3	No control programme taking responsibility 4	No control programme taking responsibility 5-Extremely important	No control programme taking responsibility N/A
Expensive cost of the product (price is too high)	Expensive cost of the product (price is too high) 1-Not at all important	Expensive cost of the product (price is too high) 2	Expensive cost of the product (price is too high) 3	Expensive cost of the product (price is too high) 4	Expensive cost of the product (price is too high) 5-Extremely important	Expensive cost of the product (price is too high) N/A
Lack of production (single manufacturer)	Lack of production (single manufacturer) 1-Not at all important	Lack of production (single manufacturer) 2	Lack of production (single manufacturer) 3	Lack of production (single manufacturer) 4	Lack of production (single manufacturer) 5-Extremely important	Lack of production (single manufacturer) N/A
Complicated procurement mechanisms	Complicated procurement mechanisms 1-Not at all important	Complicated procurement mechanisms 2	Complicated procurement mechanisms 3	Complicated procurement mechanisms 4	Complicated procurement mechanisms 5-Extremely important	Complicated procurement mechanisms N/A

Other (please specify)

Question Title

* 7. Do you think the procurement of diagnostic and drugs for leishmaniasis should be integrated with the procurement for other essential medicines?

Yes

Not sure

Question Title

* 8. Why or why not?

Question Title

* 9. On a scale from 1 (not at all relevant) to 5 (extremely relevant), please rate how important you think is that action. By importance, we mean how likely that action is to succeed to overcome the barriers.

	1-Not at all relevant	2	3	4	5 Extremely relevant
Emergency stock at capital level	Emergency stock at capital level 1-Not at all relevant	Emergency stock at capital level 2	Emergency stock at capital level 3	Emergency stock at capital level 4	Emergency stock at capital level 5 Extremely relevant	Emergency stock at capital level
Reduce the price	Reduce the price 1-Not at all relevant	Reduce the price 2	Reduce the price 3	Reduce the price 4	Reduce the price 5 Extremely relevant	Reduce the price
Integrate the supply channel with the central ones	Integrate the supply channel with the central ones 1-Not at all relevant	Integrate the supply channel with the central ones 2	Integrate the supply channel with the central ones 3	Integrate the supply channel with the central ones 4	Integrate the supply channel with the central ones 5 Extremely relevant	Integrate the supply channel with the central ones
Encourage more producers of the product, including generics	Encourage more producers of the product, including generics 1-Not at all relevant	Encourage more producers of the product, including generics 2	Encourage more producers of the product, including generics 3	Encourage more producers of the product, including generics 4	Encourage more producers of the product, including generics 5 Extremely relevant	Encourage more producers of the product, including generics
Training of the staff on better supply management	Training of the staff on better supply management 1-Not at all relevant	Training of the staff on better supply management 2	Training of the staff on better supply management 3	Training of the staff on better supply management 4	Training of the staff on better supply management 5 Extremely relevant	Training of the staff on better supply management
Pooled procurement between countries	Pooled procurement between countries 1-Not at all relevant	Pooled procurement between countries 2	Pooled procurement between countries 3	Pooled procurement between countries 4	Pooled procurement between countries 5 Extremely relevant	Pooled procurement between countries
National control programme ownership of procurement	National control programme ownership of procurement 1-Not at all relevant	National control programme ownership of procurement 2	National control programme ownership of procurement 3	National control programme ownership of procurement 4	National control programme ownership of procurement 5 Extremely relevant	National control programme ownership of procurement
Improve distribution practices	Improve distribution practices 1-Not at all relevant	Improve distribution practices 2	Improve distribution practices 3	Improve distribution practices 4	Improve distribution practices 5 Extremely relevant	Improve distribution practices

Other (please specify)

Question Title

* 1. Which of the anti-leishmanial commodities below that you/your agency had/have been procuring? (Check all that apply)

Question Title

* 2. How have you previously procured leishmaniasis medicines and diagnostics for countries in eastern Africa?

Question Title

* 3. In your view, which of the issues below was the most important in procurement of leishmaniasis drugs and diagnostics?

Question Title

* 4. Have you experienced delay in the procurement of any of the anti leishmanial drug?

Question Title

* 5. What was the reason for the last procurement delay?

Question Title

Question Title

* 7. Do you think the procurement of diagnostic and drugs for leishmaniasis should be integrated with the procurement for other essential medicines?

Question Title

* 8. Why or why not?

Question Title

* 9. On a scale from 1 (not at all relevant) to 5 (extremely relevant), please rate how important you think is that action. By importance, we mean how likely that action is to succeed to overcome the barriers.

Question Title

* 10. If you can choose one priority action to improve procurement for anti-leishmanial medicines and diagnostics, what would it be?